Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03600441 · ClinicalTrials.gov registry record · Phase 2
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
A Phase 2 study of Follicular Lymphoma, sponsored by Xynomic Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 139
- Enrollment target
- 15
- Study locations
NCT03600441 is a Phase 2 study of Follicular Lymphoma that is active but no longer recruiting, run by Xynomic Pharmaceuticals. The registered enrollment target is 139 participants, roughly in line with the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target. The trial reports 15 study locations across 9 states.
The verdict
NCT03600441, a Phase 2 study of Follicular Lymphoma, is active but no longer recruiting, sponsored by Xynomic Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 139 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.
Conditions Studied
Interventions
- DRUG Abexinostat
Study Locations (15)
Other
- Hospital Universitario Vall d'Hebrón - Barcelona
- Hospital del Mar - Barcelona
- C.H. Regional Reina Sofia - Córdoba
- Hospital Universitario Infanta Leonor - Madrid
New York
- Clinical Research Alliance Inc - Lake Success
- Manhattan Hematology Oncology Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- Arlington Cancer Center - Arlington
- Central Texas Veterans Health Care System - NAVREF - Temple
Illinois
- Advocate Medical Group - Park Ridge, Luther Lane - Oncology - Park Ridge
Kentucky
- Norton Cancer Institute - St. Matthews Campus - Louisville
Pennsylvania
- Bone Marrow Transplant Hematology Oncology Associates - Pittsburgh
Washington
- Vista Oncology Inc. PS - Olympia
Pyrénées-Orientales
- Centre Hospitalier de Perpignan - Perpignan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2018-08-27 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03600441
The ClinicalTrials.gov registry entry for NCT03600441 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target. The listed sponsor is Xynomic Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Abexinostat is the first listed.
NCT03600441 reports 15 study locations spanning 9 distinct geographic areas - top geographies include Other, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT03600441 about?
NCT03600441 is a clinical study titled "Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma". This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.
What is the current status of trial NCT03600441?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2018-08-27. Estimated completion is 2029-12-31.
What conditions does trial NCT03600441 study?
This clinical trial studies the following conditions: Follicular Lymphoma.
What interventions are being tested in trial NCT03600441?
The interventions under investigation include: Abexinostat (DRUG).
Who is sponsoring clinical trial NCT03600441?
This trial is sponsored by Xynomic Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03600441 being conducted?
This trial has 15 study locations across Illinois, Kentucky, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.